KIRhub 2.0· v2

Nintedanib

7afdca1d-7ecf-5184-9bd1-d70786010927 · FDA Approved · targets FGFR1, FGFR2, FGFR3

Nintedanib

MeasuredReference

Nintedanib targets DDR2, LCK, RET. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

DDR2 LCK RET ABL1 MELK

Top hallmarks

tumor promoting inflammation6.8k
evading apoptosis5.7k
proliferation5.3k

Top pathways disrupted

apical junction12.8k
allograft rejection12.7k
pi3k akt mtor signaling12.7k

Resistance landscape — Nintedanib

MeasuredReference

10 known oncogenic variants exist on Nintedanib's top targets — see detail for inhibition impact.

DDR2 2 known variants
- DDR2 (N456S)
- DDR2 (T654M)
RET 8 known variants

Open in new tab